Inventage Lab., Inc.
Inventage Lab is a platform technology company that specializes in Microfluidics-based Drug Delivery Systems (DDS). They have developed core platform technologies such as Laminar-FLUIDigmTM, IVL-DrugFluidic®, and IVL-GeneFluidic®, which are applied to long-acting injectable drugs and gene delivery. The company focuses on innovation, challenge, trust, and respect to contribute to improving human life and health. They have a pipeline of various long-acting formulations and collaborate with global partners. Their research centers include the IVL Formulation Center (IFC) and the IVL Platform Center (IPC), and they operate a manufacturing center (IMC) for large-scale production.
Industries
Nr. of Employees
medium (51-250)
Inventage Lab., Inc.
Patents
Sustained-release microparticles containing deslorelin, and preparation method therefor
US-12251419-B2
View DetailsSolvent removing apparatus and method of producing microsphere using the same
US-12083225-B2
View DetailsSolvent removing apparatus and method of manufacturing microsphere using the same
US-11944949-B2
View Details
Sustained-release microparticles containing deslorelin, and preparation method therefor
US-12251419-B2
View DetailsSolvent removing apparatus and method of producing microsphere using the same
US-12083225-B2
View DetailsSolvent removing apparatus and method of manufacturing microsphere using the same
US-11944949-B2
View DetailsProducts
Alzheimer's long-acting injectable (1-month formulation) — pipeline
A platform-derived long-acting injectable candidate intended as an Alzheimer’s therapeutic with a one-month dosing profile; listed as a development-stage program with a collaboration for clinical advancement.
mRNA-based antibody therapeutic (gene delivery) — pipeline
An mRNA gene-delivery program applying lipid nanoparticle formulation to produce mRNA-encoded antibody therapeutics under joint-research arrangements.
Long-acting injectables for male pattern hair loss (1‑month and 3‑month formulations) — pipeline
Sustained-release injectable candidates targeting androgenic alopecia with one-month and three-month dosing profiles developed using the platform formulation technology.
Veterinary long-acting injectables (heartworm prevention/treatment) — pipeline
Multi-month (3- and 6-month) veterinary injectable candidates for heartworm prevention and treatment developed and produced under animal-drug GMP processes.
Alzheimer's long-acting injectable (1-month formulation) — pipeline
A platform-derived long-acting injectable candidate intended as an Alzheimer’s therapeutic with a one-month dosing profile; listed as a development-stage program with a collaboration for clinical advancement.
mRNA-based antibody therapeutic (gene delivery) — pipeline
An mRNA gene-delivery program applying lipid nanoparticle formulation to produce mRNA-encoded antibody therapeutics under joint-research arrangements.
Long-acting injectables for male pattern hair loss (1‑month and 3‑month formulations) — pipeline
Sustained-release injectable candidates targeting androgenic alopecia with one-month and three-month dosing profiles developed using the platform formulation technology.
Veterinary long-acting injectables (heartworm prevention/treatment) — pipeline
Multi-month (3- and 6-month) veterinary injectable candidates for heartworm prevention and treatment developed and produced under animal-drug GMP processes.
Services
R&D and licensing of microfluidics-based drug delivery platforms and associated formulation technologies for partners.
Design and optimization of microsphere and LNP-based long-acting injectable formulations with engineered release profiles and stability testing.
Pilot and commercial-scale aseptic manufacturing services in GMP-compliant facilities for sterile long-acting injectables, including animal-drug GMP production capabilities.
Co-development programs with external partners for product development, clinical advancement and commercialization of platform-derived therapeutics.
R&D and licensing of microfluidics-based drug delivery platforms and associated formulation technologies for partners.
Design and optimization of microsphere and LNP-based long-acting injectable formulations with engineered release profiles and stability testing.
Pilot and commercial-scale aseptic manufacturing services in GMP-compliant facilities for sterile long-acting injectables, including animal-drug GMP production capabilities.
Co-development programs with external partners for product development, clinical advancement and commercialization of platform-derived therapeutics.
Expertise Areas
- Drug delivery platform development
- Long-acting injectable formulation
- Lipid nanoparticle (LNP) formulation and mRNA delivery
- Microfluidics for pharmaceutical applications
Key Technologies
- Microfluidics
- Lipid nanoparticle (LNP) formulation
- Microsphere-based sustained-release systems
- Aseptic/GMP sterile manufacturing
News & Updates
CEO Joohee Kim received the Venture Startup Promotion Award from the Prime Minister.
Inventage Lab's long-acting injection for dementia treatment received approval for Phase 1 and 2 clinical trials in Australia.
Signed a license agreement for a prostate enlargement treatment drug (IVL3013).
CEO Joohee Kim received a government award for medical technology development in 2021.
CEO Joohee Kim received the Venture Startup Promotion Award from the Prime Minister.
Inventage Lab's long-acting injection for dementia treatment received approval for Phase 1 and 2 clinical trials in Australia.
Signed a license agreement for a prostate enlargement treatment drug (IVL3013).
CEO Joohee Kim received a government award for medical technology development in 2021.